Jazz Pharmaceuticals plc

JAZZ

$172.35

+57.34% (1 year change)

Avg closing price

Price range

Market Cap

$9.51 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$601 Million

Total revenue in the last quarter.

Net Income

$148 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$4.22

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

39.87x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$206 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid . In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea . In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.

News

Cannabinoids in Focus after GW Pharmaceuticals Snapped up for €6B

Cannabinoids in Focus after GW Pharmaceuticals Snapped up for €6B

This month’s €6B acquisition of the UK heavyweight GW Pharmaceuticals by Jazz Pharmaceuticals has been hailed as a major validation of the medical cannabinoid industry.

Labiotech Labiotech, 2 months ago
Clarkson, streaking Jazz win showdown vs Simmons, 76ers

Clarkson, streaking Jazz win showdown vs Simmons, 76ers

Even without Joel Embiid, the Philadelphia 76ers were scoring every time down the court.

Fox News Fox News, 2 months ago
Jazz beat Heat 112-94 for seventh straight victory

Jazz beat Heat 112-94 for seventh straight victory

Utah turned to its defense when its outside shots weren’t falling.

Fox News Fox News, 2 months ago